Balchem Corporation, a company incorporated in 1967 and headquartered in Montvale, New Jersey, has recently released its 10-K report. The company operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Balchem develops, manufactures, and markets specialty performance ingredients and products for various markets, including nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial sectors.
In the Human Nutrition and Health segment, Balchem supplies ingredients to the food and beverage industry, including spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems. Additionally, it offers specialty vitamin K2, microencapsulation solutions, and human-grade choline nutrients.
The Animal Nutrition and Health segment provides microencapsulated products to enhance health and milk production in animals, chelation technology for enhanced nutrient absorption, and essential nutrient choline chloride for monogastric animal health.
In the Specialty Products segment, Balchem distributes performance gases and chemicals such as ethylene oxide, propylene oxide, and ammonia for various uses, including medical device sterilization, fumigation, and refrigeration. Additionally, it markets and sells chelated minerals for high-value crops.
Balchem's recent acquisitions include Bergstrom Nutrition, a leading manufacturer of MSM, and Kappa Bioscience, a specialty vitamin K2 manufacturer, strengthening the company's position in the Human Nutrition and Health segment.
The company reported a total backlog of $50,415 at the end of 2024, with the majority of sales in the plant nutrition business occurring in the first half of the year due to the seasonal nature of the business.
Balchem faces competition from both large and small companies in the supplement, food and beverage, animal nutrition, and industrial markets. The competitive environment requires substantial investments in research and development to develop new and improved products and maintain customer acceptance.
Balchem's 10-K report provides insight into the company's operations, financial condition, and risk factors, offering investors and stakeholders a comprehensive overview of its performance and prospects for the future. Today the company's shares have moved 1.5% to a price of $163.73. For more information, read the company's full 10-K submission here.
